← Eichor
Condition: Immune Thrombocytopenia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immune Thrombocytopenia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Romiplostim for Oral TPO-RA Resistant ITP
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07612319V-IMMUNE® for Immune Thrombocytopenia
Phase 3 · 2 location(s) · On Pharma Importadora, Exportadora e Distribuidora de Medica · NCT06962631A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05214391Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07206823Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopen
Phase 2/Phase 3 · 20 location(s) · argenx · NCT07194850A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/Phase 2 · 45 location(s) · Eli Lilly and Company · NCT06721013Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NA · 1 location(s) · Sohag University · NCT07093606French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT02877706Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NA · 7 location(s) · Yunfeng Cheng · NCT06479317Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07205861Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thromb
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05338190Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07513948CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed
Phase 3 · 36 location(s) · Sanofi · NCT07007962Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Phase 1 · 1 location(s) · Gliknik Inc. · NCT07605845An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06799611BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT06787989Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06352281High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patien
Phase 3 · 1 location(s) · Shandong University · NCT07559331A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05995054Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Phase 2/Phase 3 · 1 location(s) · Chinese SLE Treatment And Research Group · NCT07657793A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytop
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06094881CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.